Sam Murphy

Company: SalubrisBio

Job title: Chief Executive Officer

Seminars:

JK07: Selective ErbB4 Agonist & Potential First Disease-Modifying Biologic for Heart Failure Across the Ejection Fraction Spectrum 9:10 am

Discussing JK07, an NRG1/ErbB3 antibody fusion, and the first selective ErbB4 agonist in clinical development for heart failure, with unique potential to increase contractility and reduce fibrosis in the myocardium Evaluating phase 1b data in heart failure with reduced ejection fraction (HFrEF) subjects where the potential to increase LVEF durably with a single, well-tolerated dose…Read more

day: Summit Day 2